CLINICAL TRIAL NEWS: MM-398 combined with standard chemotherapy boosts overall survival by nearly 2 months in patients previously treated with gemcitabine. Learn more.
by PanCAN Staff — May 1, 2014
CLINICAL TRIAL NEWS: MM-398 combined with standard chemotherapy boosts overall survival by nearly 2 months in patients previously treated with gemcitabine. Learn more.
No one should face pancreatic cancer alone. Learn how we can support you.
Mon – Fri, 7 a.m. – 5 p.m. PST
You can also contact us using the below form.
Get the latest news and updates from the Pancreatic Cancer Action Network.
2101 Rosecrans Ave, Suite 3200
El Segundo, CA 90245 - Map
Phone: (310) 725-0025
Toll Free: (877) 573-9971
Fax: (310) 725-0029
Email: info@pancan.org
Mail Donations to:
Pancreatic Cancer Action Network
Donation Processing Center
Po Box 5041
Boone, IA 50950-0041
Get Our Latest News!
©2024 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy
Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.
The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.